| In Motion Therapy | |
|
611 E Star Ct, Suite B, Montrose, CO 81401-6704 | |
| (970) 249-1646 | |
| (970) 249-8899 |
| Full Name | In Motion Therapy |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Rehabilitation |
| Location | 611 E Star Ct, Montrose, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407804065 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Secondary |
| 261QR0400X | Clinic/center - Rehabilitation | (* (Not Available)) | Primary |
| Provider Name | Denise J Powers |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770801441 PECOS PAC ID: 4284659186 Enrollment ID: I20051011000005 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Luke Geer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1053546648 PECOS PAC ID: 3072532951 Enrollment ID: I20051121000643 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Teresa M Bailey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1437107737 PECOS PAC ID: 9638180888 Enrollment ID: I20060601000090 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Susan G Scranton |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1780738856 PECOS PAC ID: 9032212147 Enrollment ID: I20070309000507 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Amy L Hanley |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1164669826 PECOS PAC ID: 8820154941 Enrollment ID: I20090225000429 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Ryan Christopher Williams |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1578838595 PECOS PAC ID: 8426219361 Enrollment ID: I20120419000591 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Troy P Grignon |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1992131692 PECOS PAC ID: 3678701943 Enrollment ID: I20140113000654 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Kimberly A Schwarz |
|---|---|
| Provider Type | Practitioner - Qualified Speech Language Pathologist |
| Provider Identifiers | NPI Number: 1538393756 PECOS PAC ID: 4688991672 Enrollment ID: I20150401001185 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Richard Wagner |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770962805 PECOS PAC ID: 3072821214 Enrollment ID: I20151007002464 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Kristin L Tea |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1982096095 PECOS PAC ID: 6305137449 Enrollment ID: I20160621002541 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Kari A Reddin |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1851737720 PECOS PAC ID: 0648556498 Enrollment ID: I20170411002069 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Anne Keil |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912405978 PECOS PAC ID: 0345596508 Enrollment ID: I20180702002323 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Tesse Maciejko |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1366092272 PECOS PAC ID: 7911238191 Enrollment ID: I20191021000725 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Martin S Lutz |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1750854014 PECOS PAC ID: 0042558967 Enrollment ID: I20200827001394 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Amanda Stertzbach |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1467069872 PECOS PAC ID: 5193145985 Enrollment ID: I20201016000230 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Daven Valdez |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1427637453 PECOS PAC ID: 0143629022 Enrollment ID: I20210526001877 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Katelyn M Wilhelm |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1871043521 PECOS PAC ID: 8628359106 Enrollment ID: I20210719003152 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Nicholas H Wilhelm |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1669929964 PECOS PAC ID: 0345538856 Enrollment ID: I20210720000493 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Abigail Jayne Mihulka |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1679240766 PECOS PAC ID: 7416320916 Enrollment ID: I20230303001149 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Nicholas Louis Blonski |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1396414892 PECOS PAC ID: 5395142632 Enrollment ID: I20230316002801 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Emily Brent |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528766557 PECOS PAC ID: 8123493822 Enrollment ID: I20230411002500 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Provider Name | Emily Brent |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1528766557 PECOS PAC ID: 8123493822 Enrollment ID: I20230606000551 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| In Motion Therapy 611 E Star Ct, Suite B, Montrose, CO 81401-6704 Ph: (970) 249-1646 | In Motion Therapy 611 E Star Ct, Suite B, Montrose, CO 81401-6704 Ph: (970) 249-1646 |
News Archive
Sosei Group Corporation, announces that its wholly owned subsidiary Activus Pharma Co., Ltd. is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.
Local businesses and the Change Your Game! Foundation will rally efforts to benefit breast cancer research and the Susan G. Komen for the Cure, Phoenix Affiliates on Saturday, March 6th, 2010 beginning at 8:30am.
Advanced non-small cell lung cancer (NSCLC) patients have few effective treatment options and low 5-year survival rates. The checkpoint inhibitors MEDI4736 and tremelimumab have both demonstrated acceptable safety and potential efficacy when used as single-agents in several different types of cancer.
Iran has the third-highest number of coronavirus disease (COVID-19), deaths after China and Italy, the highest in Western Asia, and the fourth-highest number of SARS-CoV-2 cases, surpassed by only Mainland China, South Korea, and Italy. The country reported its first COVID-19 case on February 20.
Two previously unrecognized genetic markers may predict whether breast cancer patients would benefit from chemotherapy followed by tamoxifen, according to preclinical research from Roswell Park Cancer Institute, in collaboration with the cooperative research group SWOG and St. Jude Children's Research Hospital. The results of this research will be presented at the American Association for Cancer Research Annual Meeting 2016, to be held April 16-20 in New Orleans.
› Verified 6 days ago